Pharmaceutical

MiNA and Nippon Shinyaku enter RNAa therapeutics deal

MiNA Therapeutics has entered into an agreement with Nippon Shinyaku to develop RNAa therapeutics for rare neurodegenerative ailments.

Apr 7, 2024 - 00:00
MiNA and Nippon Shinyaku enter RNAa therapeutics deal
MiNA Therapeutics has entered into an agreement with Nippon Shinyaku to develop RNAa therapeutics for rare neurodegenerative ailments.
Read the original article

Tags:

Previous Article

Acumen and Lonza to produce Alzheimer’s drug sabirnetug

Next Article

Caris and Merck KGaA link to develop ADCs for cancer treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi backs development of Graviton’s treatments for serious diseases

Sanofi backs development of Graviton’s treatments for s...

Feb 2, 2024

STAT+: In the U.S., scientists see barriers to the development of CAR-T cell therapies. In Spain, a hospital brews its own

STAT+: In the U.S., scientists see barriers to the deve...

Dec 19, 2023

JAMA’s new editor settles in, bringing open access and other changes

JAMA’s new editor settles in, bringing open access and ...

Mar 19, 2023